Next Article in Journal
Identifying the Ion Channels Responsible for Signaling Gastro-Intestinal Based Pain
Next Article in Special Issue
Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration
Previous Article in Journal
Dendritic Cell Regulation by Cannabinoid-Based Drugs
Previous Article in Special Issue
Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

Clinical Toxicities of Histone Deacetylase Inhibitors

TRI, Inc., 6500 Rock Spring Dr, Bethesda, MD 20817, USA
Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(9), 2751-2767;
Received: 23 June 2010 / Revised: 18 August 2010 / Accepted: 19 August 2010 / Published: 26 August 2010
(This article belongs to the Special Issue HDAC Inhibitors)
The HDAC inhibitors are a new family of antineoplastic agents. Since the entry of these agents into our therapeutic armamentarium, there has been increasing interest in their use. Although this family comprises chemical compounds from unrelated chemical classes that have different HDAC isoform specificities, they surprisingly have very similar toxicity profiles. In contrast, the observed toxicity profile is somewhat different from that of traditional cytotoxic chemotherapeutic agents and from other epigenetic agents. While some of the side effects may be familiar to the oncologist, others are less commonly seen. As some patients remain on therapy for a prolonged period of time, the long-term sequelae need to be characterized. In addition, since preclinical models suggest promising activity when used in combination with other antineoplastic agents, combination trials are being pursued. It will thus be important to distinguish the relative toxicity attributed to these agents and be alert to the exacerbation of toxicities observed in single agent studies. Notably, few of the agents in this class have completed phase 2 testing. Consequently, more clinical experience is needed to determine the relative frequency of the observed side effects, and to identify and develop approaches to mitigate potential clinical sequelae. View Full-Text
Keywords: histone deacetylase inhibitors; HDAC; toxicities; chemotherapy; clinical trial; HDI histone deacetylase inhibitors; HDAC; toxicities; chemotherapy; clinical trial; HDI
MDPI and ACS Style

Subramanian, S.; Bates, S.E.; Wright, J.J.; Espinoza-Delgado, I.; Piekarz, R.L. Clinical Toxicities of Histone Deacetylase Inhibitors. Pharmaceuticals 2010, 3, 2751-2767.

AMA Style

Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Clinical Toxicities of Histone Deacetylase Inhibitors. Pharmaceuticals. 2010; 3(9):2751-2767.

Chicago/Turabian Style

Subramanian, Srividya, Susan E. Bates, John J. Wright, Igor Espinoza-Delgado, and Richard L. Piekarz 2010. "Clinical Toxicities of Histone Deacetylase Inhibitors" Pharmaceuticals 3, no. 9: 2751-2767.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop